Karyopharm Therapeutics Inc Overview
Industry: Biotechnology & Medical Research
Sector: Healthcare
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export ( Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Karyopharm Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $29.2M (+38% YoY); EPS was $22 (reported).
Revenue
$29.2M
+38% YoY
EPS
$22
reported
Net loss
-$22.4M
reported
Cash
$91.2M
reported
What changed
- Revenue +38% YoY to $29.2M; EPS reported to $22.
Guidance / outlook
we expect several important developments that have the potential to create significant value for the Company, while improving outcomes for patients.
Earnings material
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 14, 2026
SEC filing
8-K
May 14, 2026
SEC filing
10-K
Feb 13, 2026
Earnings release
Earnings release
Feb 12, 2026
SEC filing
8-K
Feb 12, 2026
SEC filing
8-K
Jan 12, 2026
SEC filing
10-Q
Nov 03, 2025
SEC filing
8-K
Nov 03, 2025
Earnings release
Earnings release
Nov 03, 2025
SEC filing
8-K
Oct 08, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Karyopharm: "Hold" Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI)
Headline from Seeking Alpha: Karyopharm: "Hold" Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI).
Karyopharm: 'Hold' Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI)
Headline from Seeking Alpha: Karyopharm: 'Hold' Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI).
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI)
Headline from Seeking Alpha: Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI).
Karyopharm drops 21% following disclosure of executive cash retention plan
Headline from Seeking Alpha: Karyopharm drops 21% following disclosure of executive cash retention plan.
Earnings Per Share
Score 3.00/5
Karyopharm Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology & Medical Research industry
, Syneos Health
, Pluri Inc
, Prenetics Global Ltd
are companies with high ratings.
Return on Equity
Score 2.87/5
Karyopharm Therapeutics Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 1.53/5
Karyopharm Therapeutics Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.12/5
Karyopharm Therapeutics Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios